Ticagrelor Tablet, Film Coated
Product Images NDC 67296-2268

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 67296-2268). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 10 (Ticagrelor 10figure)

A Kaplan-Meier cumulative incidence plot comparing Ticagrelor 90 mg and Clopidogrel over 360 days from randomization. The y-axis represents cumulative percentage of events, while the x-axis shows days from randomization. The plot includes sample sizes and statistical results for each treatment group.*

FDA Label Image

Figure 11 (Ticagrelor 11figure)

A forest plot comparing the treatment effects of Ticagrelor versus Clopidogrel across various patient characteristics including geographic region, ASA dose, treatment approach, PCI timing, CABG status, diabetes history, prior stroke, inhibitor use, age, sex, and race. The plot shows hazard ratios with 95% confidence intervals indicating relative efficacy, with a vertical line at HR=1 separating Ticagrelor and Clopidogrel benefit.*

FDA Label Image

Figure 12 (Ticagrelor 12figure)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel based on ASA dose categories (>=300 mg, >100 to <300 mg, <=100 mg) and region (US and Non-US). The horizontal axis ranges from 0.125 to 8, indicating effectiveness where values less than 1 favor Ticagrelor and greater than 1 favor Clopidogrel. The chart visually presents numeric data for sample size and event count for each subgroup.*

FDA Label Image

Figure 13 (Ticagrelor 13figure)

A Kaplan-Meier curve graph showing cumulative percentage over days from randomization comparing Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The graph includes a table with patient numbers, events, hazard ratios, confidence intervals, and p-values. The x-axis represents time in days, and the y-axis represents cumulative percentage. A risk table below lists patient counts at various time points for each group.*

FDA Label Image

Figure 14 (Ticagrelor 14figure)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo across multiple patient characteristics including age, sex, race, weight, BMI, geographic region, history of myocardial infarction, type of qualifying MI, diabetes mellitus status, coronary artery disease status, creatinine clearance, history of PCI, stent type, smoking status, and prior ADP receptor blocker treatment duration.*

FDA Label Image

Figure 15 (Ticagrelor 15figure)

A line graph comparing cumulative percentage (%) of an event over months from randomization for Ticagrelor versus Placebo groups. The x-axis shows months from 0 to 54, while the y-axis shows cumulative percentage from 0 to 14%. Two lines represent Ticagrelor (solid line) and Placebo (dashed line), with sample sizes noted. Numbers at risk over time are shown below the graph for both groups.*

FDA Label Image

Figure 16 (Ticagrelor 16figure)

A forest plot chart showing comparative hazard ratios (HR) with 95% confidence intervals for various patient characteristics between Ticagrelor and placebo groups. The chart visually presents HR values for subgroups based on age, sex, race, body mass index, geographic region, baseline aspirin dose, baseline HbA1c, baseline eGFR, insulin use, history of angina, multivessel coronary artery disease, PCI history, stent presence, time since most recent PCI, history and time since most recent CABG, smoking status, and diabetes duration, illustrating relative outcomes for Ticagrelor versus placebo.*

FDA Label Image

Figure 17 (Ticagrelor 17figur)

A cumulative percentage line chart comparing Ticagrelor 90 mg bid to placebo over approximately 34 days from randomization. The y-axis shows cumulative percentage, and the x-axis shows days from randomization. The chart includes event counts and Kaplan-Meier percentages for each group, depicting lower cumulative events for Ticagrelor compared to placebo. Risk table values are shown below.*

FDA Label Image

Figure 18 (Ticagrelor 18figur)

A forest plot chart comparing the hazard ratios (HR) and 95% confidence intervals (CI) for Ticagrelor versus placebo across various patient characteristics including age, sex, race, weight, BMI, geographic region, clinical history, and smoking status. The chart displays numerical data and graphical HR indicators showing relative benefits for Ticagrelor or placebo.*

FDA Label Image

Figure 1 (Ticagrelor 1figure)

A Kaplan-Meier curve comparing cumulative event percentages over 360 days post first drug dose for Ticagrelor 90 mg and Clopidogrel. The vertical axis shows cumulative % events; the horizontal axis shows days from first dose. Ticagrelor shows a higher cumulative event rate than Clopidogrel. Risk numbers for each group are shown below the time axis.*

FDA Label Image

Figure 2 (Ticagrelor 2figure)

A bar chart illustrating the percentage of patients who experienced an event following CABG surgery over a period of 8 or more days. The x-axis represents days post-surgery, and the y-axis shows the percentage of affected patients. The chart compares two groups labeled 'T' and 'C' with corresponding numerical sample sizes shown below each day. Bars indicate event percentages for each group over time.*

FDA Label Image

Figure 3 (Ticagrelor 3figure)

A line graph showing cumulative percentage (%) over months from randomization comparing Ticagrelor (solid line) and placebo (dashed line) groups. The graph includes the number of patients at risk (N) for each group at various time points, with Ticagrelor having a higher cumulative event percentage than placebo over approximately 54 months. A legend explains T = Ticagrelor, P = Placebo, and N = Number of patients.*

FDA Label Image

Figure 4 (Ticagrelor 4figure)

A cumulative percent line graph comparing Ticagrelor 90 mg twice daily versus placebo over approximately 34 days from randomization. The y-axis shows cumulative percentage, and the x-axis shows days from randomization. The graph includes event counts and Kaplan-Meier percentages for both groups, with Ticagrelor showing higher cumulative events. A table below the x-axis lists the number of patients at risk over time for each group.*

FDA Label Image

Figure 5 (Ticagrelor 5figure)

Line graph showing IPA (%) induced by 20uM ADP over time (hours) comparing Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor demonstrates the highest IPA percentage reaching about 90% by hour 2, Clopidogrel shows moderate increase up to about 50%, and Placebo remains near zero with slight increase by hour 8.*

FDA Label Image

Figure 6 (Ticagrelor 6figure)

A line graph comparing platelet inhibition activity (IPA %) over time (days) for Ticagrelor, Clopidogrel, and Placebo induced by 20uM ADP. Ticagrelor shows the highest initial IPA, followed by Clopidogrel and Placebo with minimal effect. An inset graph presents the same data over 48 hours, highlighting early IPA differences among treatments.*

FDA Label Image

Figure 7 (Ticagrelor 7figure)

This is a chart depicting the mean effect and 90% confidence intervals for ticagrelor and a comparator (AR-C124910XX) across intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and hepatic impairment. The chart shows pharmacokinetics parameters Cmax and AUC relative to reference, with recommendations of no dose adjustments for these factors.*

FDA Label Image

Figure 8 (Ticagrelor 8fig)

A forest plot chart illustrating the mean effect and 90% confidence interval (CI) for Ticagrelor interaction with various drugs including CYP3A4 inhibitors, inducers, and other agents. The horizontal axis shows change relative to reference, with data points and error bars for each interacting drug. The chart lists recommendations for each interaction, such as avoiding concomitant use or dose adjustment, alongside the drug names and dosages.*

FDA Label Image

Figure 9 (Ticagrelor Figure 9)

A chart depicting the interaction effects of Ticagrelor doses on various co-administered drugs including Simvastatin 80 mg, Atorvastatin 80 mg, Levonorgestrel 0.15 mg, Ethinyl Estradiol 0.03 mg, Tolbutamide 500 mg, Digoxin 0.25 mg, and Cyclosporine 600 mg. The graph shows mean effect and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC, along with dosing recommendations, such as dose adjustments or monitoring guidance.*

FDA Label Image

Structure (Ticagrelor Structure)

Chemical structure of Ticagrelor, showing its molecular framework with various functional groups and atoms arranged as per its chemical composition.*

FDA Label Image

60 Tablets (Ticagrelor Tabs 60 mg)

Label for Ticagrelor Tablets 60 mg, oral film-coated tablets. The label shows the medication name, strength, quantity of 60 tablets, manufacturer information (Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, USA), and storage instructions. It includes a barcode with NDC 62332-500-60 and states 'Rx only.'*

FDA Label Image

30 Tablets (Ticagrelor Tabs 90 mg)

Ticagrelor Tablets 90 mg film-coated oral tablets label. The label shows NDC 62332-241-30 and indicates a package size of 30 tablets. It includes dosage information, storage instructions, warnings, and manufacturer details for Alembic Pharmaceuticals Limited. The label also features barcodes, branding, and a note for pharmacists to dispense the medication guide to patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.